Deciphering Depression-Targeted Mechanisms of Pandanus odorifer Leaf Extracts Based on Component Analysis and Integrated Molecular Approaches

Abstract

Introduction: Mental health is a worldwide health problem. Antidepressants have therapeutic effects but after prolonged use, they can cause unwanted side effects. Seeing the great potential of coastal plants such as sea pandanus (Pandanus odorifer) attracts attention in creating a more effective and safe treatment. The aim of this study is to identify the compounds contained in sea pandanus and elucidate the molecular mechanism in the target proteins of depressive diseases. Materials and methods: LC-MS has been used to identify compounds in sea pandanus. The network pharmacology approach used Cytoscape 3.9.1, OMIM, Disgenet, SEA, SwissTarget, STRING 2.0.0, Metascape, and Kyoto Encyclopedia of Genes and Genomes (KEGG) to predict the molecular antidepressant mechanism of the metabolite compounds. Validation was achieved using MOE with MAOA receptor (PDB ID: 2Y5Z). Molecular dynamics simulation using Maestro Schrödinger 2020-1 software. Results and discussion: A total of 19 active compounds were identified through LC-MS. Network pharmacology analysis showed that the MAOA target was the most influential protein target in the network pharmacology study of antidepressants from metabolite compounds of sea pandanus methanol extract. The results of in silico validation and molecular dynamics simulation support the network pharmacology findings. Benzylcarbonyl-Lys-Dab-Arg-NH2 compound showed higher affinity to MAOA receptor target compared to standard drug (fluoxetine) with S score −10.7455 kcal/mol and MMGBSA value −68.0669 kcal/mol. Conclusions: The compound Benzylcarbonyl-Lys-Dab-Arg-NH2 showed higher binding affinity towards MAOA compared to the native ligand and drug fluoxetine, also maintaining a s2interaction within the MAOA active site, indicating that Pandanus odorifer has significant promise as a novel antidepressant agent. These findings provide a strong basis for further investigation into its efficacy and safety in a clinical setting, potentially leading to the development of more effective and targeted treatments for depression.